About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Benefits of Transcatheter Aortic Valve Replacement Over 3 Years Confirmed By Study

by Rukmani Krishna on October 29, 2012 at 11:30 PM
Font : A-A+

 Benefits of Transcatheter Aortic Valve Replacement Over 3 Years Confirmed By Study

Transcatheter aortic valve replacement (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery, finds a study. At the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, the results of the PARTNER Cohort B trial were presented. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

TAVR is the recommended treatment for patients with severe aortic stenosis who are not suitable candidates for surgery. Outcomes beyond two years in such patients have not yet been extensively studied.

Advertisement

Inoperable patients with severe symptomatic aortic stenosis (AS) were randomly assigned to transfemoral TAVR or to standard therapy (which often included balloon aortic valvuloplasty) in the PARTNER trial. Data on three-year outcomes were analyzed according to intention to treat (ITT).

A total of 358 patients underwent randomization at 21 centers. The Kaplan Meier estimated rates of death at three years were 54.1 percent in the TAVR group and 80.9 percent in the standard-therapy group (P<0.0001); corresponding rates of cardiac death were 41.4 percent and 74.5 percent (P<0.0001). The survival advantage associated with TAVR that was initially observed at one year persisted during the subsequent years.
Advertisement

"After three years of follow-up, the benefits of TAVR were sustained as measured by all cause mortality, cardiovascular mortality, repeat hospitalization, and functional status," said one of the investigators, E. Murat Tuzcu, MD. Dr. Tuzcu is Professor of Medicine and Vice-Chairman of the Department of Cardiology in the Sydell and Arnold Heart & Vascular Institute at the Cleveland Clinic.

"Three-year data continue to support the role of TAVR as the standard-of-care for symptomatic patients with aortic stenosis who are not surgical candidates," said Dr. Tuzcu.

The results of PARTNER Cohort B Three Year will be presented on Wednesday October 24 at 12:17 PM EST in the Main Arena (Hall D) of the Miami Beach Convention Center.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
COVID Toes
International Yoga Day 2022 - 'Yoga for Humanity'
Wearable Devices Are Now Transforming Depression, Multiple Sclerosis, and Epilepsy Management.
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Aortic Valve Stenosis Infective Endocarditis Bicuspid Aortic Valve 

Most Popular on Medindia

The Essence of Yoga Blood Pressure Calculator Loram (2 mg) (Lorazepam) Drug - Food Interactions Calculate Ideal Weight for Infants Blood - Sugar Chart Find a Doctor Turmeric Powder - Health Benefits, Uses & Side Effects Vent Forte (Theophylline) A-Z Drug Brands in India

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use